A rise in BCR-ABL transcript levels detected during imatinib therapy for Ph positive CML patients who achieved CCyR is an alarming indicator of suboptimal response and should trigger a subsequent, more stringent, RT-qPCR assessment [25]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.